Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft synthesis: Human evidence for BPC-157 — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-107/3
Series
Public comment period
Version
1.0
Published
22 Apr 2025
Last reviewed
22 Apr 2025
Next review
22 Apr 2026
Identifier
10.71829/cei.cp.107
Certainty
Not rated
Cycle
2025 Q1
Window
05 Feb 2025 – 02 Apr 2025
Status
Closed
Submissions
4

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-BPC-157-HUMA/003Sigrún VercingetorixEfficacy outcomes are rated for certainty and harms are notAccepted
DRAFT-BPC-157-HUMA/002Dr Wilhelmina Oppenheimer-AdeThe same concept is given three different names in one documentAccepted
DRAFT-BPC-157-HUMA/004Dr Odalys Thorsby-NakamuraThe search date is not on the face of the documentAccepted
DRAFT-BPC-157-HUMA/001Dr Anselm MountstephenStudies not published in English were excluded without assessmentAccepted in part
4 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted3The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part1Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment0The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted0The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. Efficacy outcomes are rated for certainty and harms are not — arising from DRAFT-BPC-157-HUMA/003. Every reported harm now carries a certainty rating on the same scale as the efficacy outcomes, with the downgrade reasons stated, and discontinuation for adverse events appears in the summary of findings rather than in an annex.
  2. The same concept is given three different names in one document — arising from DRAFT-BPC-157-HUMA/002. A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.
  3. The search date is not on the face of the document — arising from DRAFT-BPC-157-HUMA/004. The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.
  4. Studies not published in English were excluded without assessment — arising from DRAFT-BPC-157-HUMA/001. Language restriction is removed from the protocol for the series, the records previously excluded on that ground are listed with their screening outcome, and the residual limitation is stated in the abstract of this review.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.